Characterizing the Microbiome of Dysbiosis
Disturbances of the intestinal microorganisms can compromise the health of the host. Persistent imbalanced states that lead to disease are referred to as dysbioses. Several patterns of dysbiosis have been associated with particular diseases. However, we are still a long way from being able to definitely conclude that certain patterns of bacteria are always (or often) associated with a particular condition. Our research focus is to characterize these patterns from a variety of diseases to understand which features might be mechanistically linked to a particular pathology.
Human Microbiota Associated Mouse Model
Microbiology has historically been linked to clinical outcomes through the germ theory of disease and Koch's postulates, where pathogenic microorganisms can be identified, cultured, and tested to confirm their roles in communicable diseases. However, the recent attention to microbiome research primarily concerns the association of gut bacteria with non-communicable diseases like obesity, inflammatory bowel diseases, and cancers. This creates a need for a new model to confirm and test the role of microbial communities, many of the members of which cannot be cultured and have uncharacterized physiology. Our group is attempting to address this need using a human microbiota associated mouse model. This model allows engraftment of human intestinal microbiota at similar levels to that in germ-free mice and provides a novel platform to test host-microbe interactions in a translational animal model.
We collaborate with a wide variety of highly motivated physician scientists, and our on-going research projects include:
- Characterizing a continuum of dysbiotic states associated with obesity
- Determining causal mechanisms of the microbiota using human microbiota-associated mouse model
- Using human microbiota-associated mouse models to understand tumor-microbiome interactions
- Evaluating how treatments for acute leukemia and stem cell transplantation disrupt the microbiome and compromise the intestinal barrier
- Optimizing encapsulated fecal microbiota preparations to treat:
- Recurrent Clostridium difficile infections
- Inflammatory bowel diseases